(Q36955091)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

main subject

metastatic breast cancer

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Michelino De Laurentiis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Giuseppe Cancello

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Emilia Montagna

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Diego D'Agostino

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Mario Giuliano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Giuseppe Di Lorenzo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Monica Plaitano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Sabino De Placido

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

language of work or name

1 reference

16 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

published in

Breast Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

R60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1186/bcr2119

10 January 2020

exact match

0 references

cites work

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2575533

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

29 September 2017

1 reference

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

21 January 2018

1 reference

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

21 January 2018

1 reference

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18631394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18631394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/BCR2119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

10 January 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18631394%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

PubMed publication ID

18631394

1 reference